 NEWARK, Calif., Dec. 10, 2020 PRNewswire -- Protagonist Therapeutics, Inc. Nasdaq: PTGX, a clinical stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 4,761,904 shares of its common stock at a price to the public of... 